Eden Research plc
LSE : EDE

November 11, 2010 10:21 ET

Debt conversion and Directors' Interests

                                                                             GB0001646941/GBP/PLUS-exn
                                                                                      11 November 2010
                                                                                                      
                                                   
                                           EDEN RESEARCH PLC
                                         ("Eden" or "Company")
                               Debt conversion and Directors' Interests
Eden  Research plc, a leading UK agrochemical development company, is pleased to announce  that  Clive
Newitt  and  Alex Abrey, Directors of the Company, have converted GBP 9,000 and GBP 5,000 respectively
of short term debt into 72,000 ordinary shares and 40,000 ordinary shares in the Company at a price of
12.5p.

In  addition a further GBP 647,994 of long term debt has been converted into 5,183,952 ordinary shares
in the Company, also at a price of 12.5p.

Following this debt conversion, Eden has 67,028,351 ordinary shares in issue and the Directors are now
interested  in  a  total  of 1,361,893 ordinary shares, representing 2.03 per cent  of  the  Company's
enlarged issued share capital, as follows:

Director             No of shares held     % of enlarged
                                           share capital

A Abrey                        155,940              0.23
K Brooks                       786,010              1.17
B Gill                         240,848              0.36
C Newitt                       179,095              0.27


The Directors of Eden are responsible for the contents of this announcement.


Enquiries:

Eden Research plc                                                        01993 862761
Clive Newitt, Managing Director

St Helens Capital Partners LLP                                           020 7368 6959
Mark Anwyl


Contact Information

  • Eden Research plc